NodThera, a developer of treatments for conditions caused by chronic inflammation, has completed a Novo Ventures-led round that also featured Sanofi Ventures.
Novo Ventures, a corporate venturing subsidiary of pharmaceutical firm Novo, led a $55m series B round for NodThera, a UK-based developer of therapeutics for inflammation-related diseases.
The round included Sanofi Ventures, the corporate venture capital arm of pharmaceutical company Sanofi, and F-Prime Capital, a subsidiary of financial services and investment group Fidelity, as well as Cowen Healthcare Investments, 5AM Ventures, Sofinnova Partners and Epidarex Capital.
Spun off from drug discovery services provider Selvita in 2016, NodThera is developing treatments for…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
